Leuko-Labs develops healthcare equipment to monitor white blood cells in neutropenia and chemotherapy patients: a non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not always readily accessible - often requiring the patient to travel, be subjected to blood draws and deal with the whole laboratory infrastructure. Use of the firm's white blood cell monitoring device - PointCheck - enables immunosuppressed patients to be tested more frequently, often representing both an improved quality of life and better clinical outcomes.
